Drug Trial Radar · NCT00673387
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Last checked: Nov 20, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
636
Actual
Start
Apr 2008
Primary completion
Apr 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.
Conditions
- Overweight
- Obesity
Interventions
pramlintide acetateDrug
subcutaneous injection, twice a day
metreleptinDrug
subcutaneous injection, twice a day
placebo-PDrug
subcutaneous injection, twice a day
placebo-MDrug
subcutaneous injection, twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable PopulationTime frame: Baseline to Week 28
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Chandler, Arizona
Research Site
Santa Rosa, California
Research Site
Walnut Creek, California
Research Site
Denver, Colorado
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Pembrook Pines, Florida
Research Site
Plantation, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Springfield, Illinois
Research Site
Overland Park, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Auburn, Maine
Research Site
Boston, Massachusetts
Research Site
Edina, Minnesota
Research Site
St Louis, Missouri
Research Site
Butte, Montana
Research Site
New York, New York
Research Site
Statesville, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Eugene, Oregon
Research Site
Medford, Oregon
Research Site
Anderson, South Carolina
Research Site
Greer, South Carolina
Research Site
Mt. Pleasant, South Carolina
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
San Antonio, Texas
Research Site
Salt Lake City, Utah
Research Site
Norfolk, Virginia
Research Site
Belingham, Washington
Research Site
Olympia, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.